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Abstract  
Recent researches for developing countries suggest knowledge generating activates is no silver 
bullet for productivity growth. In this context, this paper examines the impact of R&D activities 
on firms’ performance for the Indian pharmaceutical industry by utilizing the data of the post 
reform period (1994-2006). The empirical analysis is performed in two stages. In first stage, we 
examine the relative productivity performance of R&D vis-à-vis non- R&D. Subsequently, we 
construct two empirical frameworks, namely, growth accounting and production function. 
Results of analysis indicate that R&D firms have productivity edge over non- R&D firms. 
Regression results based on the growth accounting framework suggest that R&D intensity has a 
positive and significant effect (15%) on TFP. The results also confirm that the performance of 
foreign firms operating in the industry is more sensitive towards R&D than the local firms. 
Furthermore, the estimation results of the production function approach indicate that the output 
elasticity to R&D capital varies from 10% to 13%. Therefore, we support the argument that 
‘manna from heaven’ impact is large and significant. 
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1. Introduction 
The pharmaceutical industry in India has completely transformed itself since around the mid-
1990s when Trade-Related Aspects of Intellectual Property Rights (TRIPS) came into effect. It is 
not only that the amount of research and development (R&D) expenditure has increased 
substantially, but also a sharp change in the structure of R&D activities has been witnessed in the 
industry. While in the past, the firms were mainly focused on development of new processes for 
manufacturing drugs, now they are also engaging aggressively in R&D for new chemical entities 
(NCEs) and modification of existing chemical entities to develop new formulations and 
compositions. Furthermore, the fiscal incentives for doing R&D have also grown significantly in 
the recent years. In this context, this study attempts to answer a question that how firms’ in-
house R&D affects their performance indirectly through total factor productivity (TFP) and 
directly on output in the Indian pharmaceutical manufacturing? The question that we deal in this 
paper is relevant and one would like to have an answer for. 
In a pioneer study Solow (1957) recognized that technological change is one of the key driving 
factors of productivity growth. Proponents of recently developed endogenous growth theories 
have also recognized its role, however, they considered it endogenous which is driven by the 
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deliberate investment of resources by profit-seeking firms (Grossman and Helpman, 1990; 
Smolny, 2000). The theory also accepts the fact that a firm’s innovation activity is crucial to its 
technological progress and productivity growth. Klette and  Grilliches (1996) extended the 
edogenous growth theory for R&D and  productivity  linkage in the context of firm and  
presented  the quality ladder model in a partial equilibrium framework. The model explains that 
R&D investment and innovations are the engine of growth. Thus, the theortical linkage between 
R&D activities and productivity of firms is well established in the literature.  
In the empirical literature too, there is no dearth of study on R&D and firm’s or plant’s 
performance. Most of these studies are invariably found to have a significant and positive effect 
of R&D on the performance of firm. However, the estimated elasticity of productivity or output 
with respect to R&D varies widely in these studies (e.g. see Griliches, 1979, 1986, Griliches and 
Mairesse, 1990, Jaffe, 1986, and Griffith et al., 2006).1 Some recent studies for the developed 
countries, for example, O’Mahony and Vecchi, (2009) suggested that knowledge generating 
activates is no silver bullet for productivity growth and ‘manna from heaven’ impact is very 
small. A closer look on the related empirical literature reveals several reasons for a wide 
variation in the elasticity estimation. First, these results are observed to vary to the type of 
industry in consideration as in R&D intensive industries, by and large, elasticity is found to be 
larger. Second, the choice of the estimation technique is another source of the divergence. In 
several studies, application of different econometric techniques has yielded wide variation in the 
results on the same data (e.g. see O’Mahony and Vecchi, 2009). Third, it is also observed that a 
vast variation exists in results between firm-level and industry-level data.2  Finally, the size of 
elasticity also depends heavily on the choice of the indicator of firm’s performance (on the 
dependent variable) i.e. output, labor productivity, TFP and profit.   
                                                 
1 Considering the example from firm-level studies, Griliches (1979, 1986) found that the elasticity to R&D in the US 
manufacturing was around 0.07.  In France, it was found that the elasticity was larger than in the US and it ranged 
between 0.09 and 0.33 (Cuneo and Mairesse, 1984; Mairesse and Cuneo, 1985). For USA, Jaffe (1986) estimated 
the elasticity around 0.20. For the same country, Griliches and Mairesse (1990) found it is ranging between 0.25 to 
0.45, while in the same study, for Japanese manufacturing it was found to be ranging between 0.20 to 0.50. 
However, for Taiwanese manufacturing firms, Wang and Tsai’s (2003) estimation suggested it as 0.19. In a recent 
paper, Griffith et al. (2006) for the UK manufacturing firms found the size of the elasticity too low (ranging from 
0.012 to 0.029).  In the case of India, the elasticity with respect to value added was calculated to be 0.064 in the 
heavy industries, 0.357 in the light industries and 0.101 in the overall industries (Raut, 1995). 
2 Firm based studies generally indicated for a greater role of R&D investment in production than industry level 
studies. 
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Against this backdrop, we are set to investigate the role of R&D on performance of firms in the 
Indian pharmaceutical industry. We take up the issue in an innovative way, and attempt to 
investigate the relationship for a very recent period (1994-2006). We take into consideration two 
important indicators of firms’ performance, namely output and TFP, for the empirical analysis. 
This investigation is very relevant from a policy perspective, mainly, because contrary to the 
general perception that pharmaceutical industry in general is very sensitive to R&D activities, the 
Indian pharmaceutical industry is known for its low research intensity. Nevertheless, in recent 
years as regulatory environment has changed, firms are exposed to intense both in national and 
international market. This has encouraged firms (in some cases forced) to adopt the innovative 
activities as the key of the growth strategy. The recent data also validate that at least some large 
firms in this industry have started taking R&D activities a bit more seriously than earlier.  
The remainder of this paper is structured methodically in sections, which are as follows: Section 
2 discusses R&D issue in the Indian pharmaceutical industry. Sections 3 explain data related 
issues and estimates TFP of the sample firms. Section 4 compares productivity of R&D and non- 
R&D firms. Section 5 constructs empirical models and estimates the effects of R&D on Firms’ 
Performance. The final section lays out concluding remarks and policy suggestions.  
2. R&D and Indian Pharmaceutical Industry 
During the postwar years and subsequently for a long period, the developing countries in general 
and India in particular had remained net users, rather than developers of R&D intensive 
pharmaceutical products. This was due to evident and obvious reasons of inadequate investment 
resources, lack of sufficient skill in medicinal chemistry and high risky uncertain nature of such 
investment and embryonic R&D infrastructure in most of these countries. Another question of 
developing countries adopting R&D and patent protection policy has been a debatable issue 
among the academia and the industry.  For example, following the writings of Penrose (1951), 
Vaitsos (1972) and Greer (1973), it has been argued that developing countries lose by granting 
patent protection since the costs of patent protection outweighs its benefits and consumers suffer 
from higher drug prices resulting from patent monopolies. In India, for instance, many of the 
pharmaceutical multinational corporations (MNCs) operated through their subsidiaries and 
enjoyed product patent regime and high price. As a case of non-affordability of drugs by a large 
section of the population, the government abolished product patent protection in 1972 and drugs 
price control was introduced.  Indian companies (along with MNCs subsidiaries) responded to 
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this situation by developing generics for our highly regulated market under the process patent 
protection of drugs. 
Even when the 1994 Agreement on Trade-Related Aspects of Intellectual Property Rights 
(TRIPs) which made mandatory product/process patent protection for World Trade Organization 
(WTO) member countries, it had again been initiated a debate that whether developing countries 
gain technologically from strong  IPRs (patent regime). Empirical investigations show rather 
mixed results. For example, Sakakibara and Branstetter (2001) show that patent regime is not 
positively correlated with R&D activities in Japan. On the contrary, Mascus and Dougherty, 
(2005) in a recent study on China proclaim a positive relation between patents and R&D.   
India signed the 1994 TRIPs Agreement and Indian companies established themselves as 
suppliers of active pharmaceutical ingredients (APIs) and intermediates to MNCs. Ever since the 
product patent regime was launched on 1 January 2005, domestic pharmaceutical companies 
have increased their allocation for R&D and their structure of R&D activities. At present, the 
Indian drug and pharmaceutical industry is ranked as the fourth largest in terms of volume and 
thirteenth in terms of value in the world. The industry accounts for about 8% of the total world’s 
drug production (OPPI, 2008). By far, the Indian industry’s forte remained in generic product 
market; and this has been propelled by reverse engineering skills and also low cost advantage. 
The pharmaceutical products price is ruled at relatively low level, both in the domestic as well as 
in export markets. Currently, Indian companies, on an average, spend about 5% turnover (OPPI, 
2008) on R&D, which is much lower as compared to companies of most of the developed 
countries where this percentage varies between 15 to 20%.  Traditionally, Western MNCs have 
dominated the pharmaceutical industry and their competitive edge has been in basic R&D, new 
drug discovery, new chemical entities (NCEs) and bio-technology supported by patent regime till 
end-2004. It is then no longer a surprise that these MNCs could invest massively in R&D, bear 
with high risk and long gestation period for new drug discovery and thereby reap monopoly 
profits. 
Why Indian companies have hitherto invested very little in R&D for new drug discovery and 
NCEs? The industry circle possibly explains this phenomenon by two important factors. First, 
the industry lacks product patent protection regime, massive investment requirement and highly 
risky nature of such investment. Second, Indian price control regime also tended to squeeze the 
profit margin which served as a disincentive to spend on R&D. 
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Nevertheless, in the recent years, the outlook of the industry has changed considerably and firms 
in India have started taking R&D activities more seriously and more money is being invested 
now in these activities (see Figure 1). There can be many reasons behind this change in the 
attitude of Indian firms relating to the R&D activities. First, fiscal incentives and government 
support has encouraged firms for R&D. Recently the government has started many new tax 
exemptions schemes and most of the old such schemes are extended.3 At second place, new 
patent regime has also encouraged and forced Indian firms to take up the R&D activities more 
seriously, if they have to survive in the market. As a result investment in R&D for developing 
new drugs has surged since TRIPS came into effect (since 2005). According to the current 
estimates there are at least 10 to 15 domestic Indian pharmaceutical companies that are active in 
drug research and have research centers across the country. Table 1 presents the share of pay-out 
on R&D by 10 large firms of the pharmaceutical industry, which demonstrates clearly that in 
recent years these firms have increased their pay-out on the innovation activity sufficiently. 
Major domestic companies such as Dr Reddy’s Lab, Ranbaxy, Wockhardt, Lupin and Cipla have 
realized that R&D is the key to success for their growth and expansion plans in this industry. 
Consequently, they have started demonstrating change in the structure of their R&D activities. 
These companies have comparative advantage in undertaking R&D activities locally as i) R&D 
expenditure in India is far lower than in developed countries and cost differentials are reflected 
in lower costs of machinery, equipment and intellectual capital; ii) India’s large population base 
facilitates clinical trials (CTs) for diseases prevalent in tropical countries; iii) Many of the Indian 
pharmaceutical firms have been accredited by regulatory agencies such as World Health 
Organization (WHO) and United State Food and Drug Administrator (US-FDA) and they have 
turned to contract research and manufacturing.   
More recently, growth through overseas acquisitions has been one of the stated strategies of large 
pharmaceutical companies to undertake risky R&D investments and, enhance the skill levels of 
                                                 
3 Some of important fiscal benefits are as follows:   
a) The benefit of weighted exemption on the income tax has been till 31st March, 2015.b) Deduction is given on tax 
to depreciation on investment made in land and building for dedicated research facilities, expenditure incurred on 
clinical trials and expenditure incurred for obtaining regulatory approvals. c) Reference Standard (sample under test) 
is exempted from import duty. e) Reference books to be imported for R&D are exempted from import duty. f) On 
the basis of recommendations of The Pharmaceutical Research and Development Committee, the government 
provides some extra fiscal incentives to R&D Intensive Companies (Gold Standard Companies). g) To fund the 
R&D initiatives of Institutions and industry, the Pharmaceutical research and Development Support Fund (PRDSF) 
has a corpus of INR 1500 million) to utilize. 
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their employees by networking and leveraging their assets. The R&D focus of these companies 
has been on biopharmaceuticals, new chemical entities (NCEs), and novel drug delivery systems 
(NDDSs).      
In this changing scenario and backdrop of findings of recent empirical literature, it becomes 
relevant to test the role of in-house knowledge activities on firms’ performance in the Indian 
pharmaceutical industry. 
 
(Source: Prowess Database, CMIE, 2008) 
Table: 1 
Percentage of R&D Expenditure to Sales of Large Firms of Indian Pharmaceutical 
Industry 
 2000 2001 2002 2003 2004 2005 2006 2007 2008 
Aurobindo Pharma Ltd. 1.92 0.86 1.25 1.85 3.65 4.67 4.39 4.86 4.88 
Cadila Healthcare Ltd. 4.74 8.32 7.50 3.88 7.76 8.96 8.86 10.14 9.20 
Cipla Ltd. 3.89 3.85 3.34 0.00 2.75 4.10 5.01 4.80 5.41 
Dr. Reddy'S Lab Ltd. 2.68 4.17 6.32 10.17 12.88 18.18 11.79 6.98 9.22 
Glaxosmithkline P. Ltd. 0.43 0.35 0.33 0.29 0.30 0.28 0.36 0.33 0.70 
Glenmark Pharma Ltd. 3.58 11.98 4.66 9.17 9.75 9.05 5.32 6.12 4.68 
Lupin Ltd. 0.74 5.45 6.10 3.57 3.84 6.86 6.29 6.93 7.27 
Orchid C & P Ltd. 1.26 3.79 4.12 5.13 5.56 7.57 6.95 6.74 5.67 
-10
0
10
20
30
40
50
60
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Figure: 1
Growth of Sales and R&D Expenditure in the Indian Pharmaceutical Industry
%Sales Growth % R&D Expendtire Growth
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Piramal Healthcare Ltd. 1.89 1.78 2.12 1.60 3.87 8.28 6.04 6.29 1.76 
Sun Pharma Inds. Ltd. 3.94 4.47 4.84 8.33 12.06 11.11 11.94 10.93 5.95 
(Source: Prowess Database, CMIE, 2008) 
 
3.Data and TFP Estimation Technique 
3.1. Data 
Firms’ data of the Indian Drug and Pharmaceutical industry are mainly obtained from the 
Prowess4 database provided by Center for Monitoring Indian Economy (CMIE). The analysis 
includes only firms (358 firms) which have consistent data in the study period (1994 to 2006). 
Details of variables, their definitions and sources are discussed in Table 1.  A descriptive 
statistics of data series is reported in Table 1A of Appendix. 
Table 2: Variables Definition and their Source, 1994-2006 
 
Variable  Definition  Data source  
Output(Y) Gross value added of the firms Prowess 
Labour input (N) Number of workers Prowess  
Physical capital (K) Computed as follows: ttt IKK +−= −1)1( δ  
where K is the capital stock, I is deflated gross 
investment, and δ is the rate of depreciation 
taken at 7%. 
Prowess 
R&D 
Intensity(R&DInt) 
R&D expenditure of firms divided by their 
sales 
Prowess 
R&D 
Capital(R&DCap) 
Annual expenditure on R&D of firms Prowess 
Export intensity 
(Export) 
Export of firms divided by their sales Prowess 
                                                 
4 Prowess Database is online database provided by the Centre for Monitoring Indian Economy (CMIE). The 
database covers financial data for over 23000 companies operating in India. Most of the companies covered in the 
Database are listed on stock exchanges, and the financial data includes all those information that operating 
companies are required to disclose in their annual reports. The accepted disclosure norms under the Indian 
Companies Act, 1956, makes compulsory for companies to report all heads of income and expenditure, which 
accounts for more than 1% of their turnover. 
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Import intensity 
(Import) 
 
 
Total import (raw material and finished goods) 
of firms divided by their sales.  
 
Prowess 
Raw materials Expenditure on raw materials of firms Prowess 
Power&fuel Expenditure on power and fuel of firms. Prowess 
Size Value of sales of firms Prowess 
Note: all series are deflated with appropriate deflator before any econometrics treatment. 
 
3.2. TFP estimation  
 
In order to examine the role of R&D on firms’ performance, firstly we need to estimate TFP of 
our sample firms. In this process, the OLS approach of measuring TFP of firms as the difference 
between actual and predicted output may lead to omitted variable bias since the firm’s choice of 
inputs is potentially correlated with unobserved productivity shocks. To overcome this problem 
we use the Levinsohn-Petrin (2003) technique. This procedure utilizes firms’ intermediate inputs 
as proxies to correct for the part of the unobserved productivity shock correlated with firms’ 
inputs. Following this approach, we estimate a Cobb Douglas production function in following 
form: 
ititititit KLnNLnYLn ηωααα ++++= )()()( 210  ………………….1 
where Y, N and K denote value added, labor and capital, respectively of firm i in year t. Ln 
indicate that series are transformed in logarithm before any econometric treatment. In this model 
(equation 1) the error has two parts: first is ω, which represents the transmitted productivity 
component, while η is an error term that is not correlated with inputs. ω is affected by firms’ 
policy, and it is unobserved (for details of this methodology, see Levinsohn-Petrin, 2003, and 
Sharma, 2010). Results of the estimated production function are reported in Table 3, which 
suggests that both inputs have significant impact on output of firms. On the basis of this 
estimation, TFP of our sample firms is predicted for further analysis.   
Table: 3 
Cobb- Douglas Production Function Estimation using Levinsohn-Petrin Productivity Estimator 
(Dependent Variable: LY) 
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Variables  Coefficient  Z-value 
Ln(K) 0.26801* 2.50 
Ln(N) 0.60809* 13.33    
Wald test (P-Value) 0.1667 
Notes:  
1. Wald test of constant returns to scale. 
2. Proxy variables: Power and fuel expenses; and Raw material expenses. 
3. * indicate statistical significance at the 5%. 
 
4. Are R&D Firms more productive than Non- R&D Firms? 
In order to examine the role of R&D, we ask an important question ‘Are R&D Firms more 
productive than Non- R&D Firms?’ To answer this question, we begin the investigation 
comparing R&D firms and non- R&D firms, by plotting their average annual estimated TFP, 
which is presented in Figure 2.  The comparison of the groups of firms reveals that firms those 
firms which have in-house R&D facilities are more productive than non-R&D firms on an 
average. Further, a closer look also reflects that before the year 2000, the difference between the 
groups was fluctuating, however, after this period the gap is consistently maintained. This is the 
first indication we receive about the R&D’s role, which is quite positive and encouraging. 
 
(Source: Author’s calculation) 
 Taking forward our investigation at the next level, we compare the distribution of TFP of both 
types of firms. We conduct a two-sided non-parametric Kolmogorov-Smirnov test (KS-test) to 
determine whether the TFP distributions between the two groups differ significantly. The KS-test 
0.29
0.31
0.33
0.35
0.37
0.39
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Figure 2
Average Estimated TFP, R&D vis-à-vis Non- R&D Firms 
Non- R&D Firms R&D Firms Overall
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calculates the largest difference between the observed and expected cumulative frequencies, 
which is called D-statistics. These statistics are compared against the critical D-statistic for the 
sample size. For this purpose, we consider three important years of the sample period: 1994, 
2003 and 2006.5 The results of the two-sided KS-test are shown in Table 4, which reveal the TFP 
distribution of R&D firms stochastically dominates those of non- R&D firms at least in the late 
reform years, i.e. 2003 and 2006. However, in the initial year (1994), the difference is not found 
to be statistically significant at any reasonable level. At this stage, we can also conclude that the 
evidence supports the hypothesis that in the whole sample of firms R&D firms stochastically 
dominate non- R&D firms at least in the recent years. 
Test 4: Kolmogorov-Smirnov tests for R&D vis-à-vis Non- R&D, 1994-2006 
Serial 
No. 
Group Largest Difference (D) 
1994 2003 2006 
1 0&&:0 ≤− DNonRDRH  0.2049 
(0.256) 
0.3314** 
 (0.032) 
0.3282* 
 (0.097) 
2  0&&:0 ≤− DRDNonRH  -0.1954 
(0.290) 
-0.0714   
(0.852) 
-0.0051     
(0.999) 
3  Combined K-S 0.2049 
(0.205) 
0.3314*    
 (0.064) 
0.3282    
 (0.194) 
Notes: 
1. P-values based on the bootstrap approximation are in parentheses. 
2. ** and * denote for statistically significant at 5% and 10%, respectively.  
 
5. Estimating the Effects of R&D on Firms’ Performance 
Now we investigate the impact of R&D on TFP and output of the sample firms.  Our study 
constructs two frameworks. The first is a growth accounting framework, which allows an 
indirect impact of R&D on productivity through TFP, within the endogenous growth framework. 
                                                 
5 1994 and 2006 are our starting and ending points, respectively, while 2003 is important because this year is a 
turning point for the Indian manufacturing from recession to boom. We also test other years (but do not report) of 
the sample and the results are almost similar. 
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This framework is followed by a production function approach, in which R&D capital directly 
enters in the aggregate production function as an input.  
 
5.1. Effects of R&D on TFP  
  
We start our empirical modeling with the growth accounting framework. Under this approach we 
broadly follow Coe and Helpman (1995) and Atella and Quintieri (2001) and test R&D intensity 
(R&D int) on the estimated TFP of firms. Therefore, our baseline empirical model to be 
estimated is as follows:  
itititit uXLnTFP +++= βγα )int D&R( ……………….2 
where TFP  and R&Dint are the level of TFP and R&D intensity, respectively of firm i in period 
t. R&D intensity is measured by the ratio of R&D expenditure to sale of firms. In the equation, X 
is a vector of firm characteristics, u is error term and ,α γ and β are parameters to be estimated. 
Ln indicates for logarithm transformation of the variables. 
We estimate equation 2 in four alternative ways and their results are reported in Table 5. Column 
1 of the table presents results of the model in which only R&D intensity is the explanatory 
variable. Columns 2, 3 and 4 include firm-specific characteristics (control variables), i.e. size, 
export intensity (export) and import intensity (import).6 Column 3 also includes a dummy for 
foreign firms (FD) (if foreign firm, FD=1, otherwise 0), while column 4 includes an interaction 
variable of foreign firm dummy and R&D intensity. One previous year’s lag of dependent 
variable is included in columns 2, 3 and 4, to tackle the potential endogeneity. The results show 
that the R&D intensity elasticity to the productivity is positive and varies from 0.15 to 0.19. This 
implies that 1% increase in R&D intensity leads to 0.15% to 0.19% increase in TFP. This 
estimate is relatively lower than the findings for France (Cuneo and Mairesse, 1984 and Hall and 
                                                 
6 To capture the export intensity of firms, we use ratio of export to value of sales of firms. Theoretically exporting 
firms make themselves more productive and efficient to compete in foreign markets, therefore we expect a positive 
impact of this variable. On the other side, the import intensity of firms is captured by total import (imports of both 
raw material and finished goods) to value of sales of firms (for detailed discussion on this issue, see Ben-David, 
1993; Sachs and Warner, 1995; Wagner, 2002; Aw et al., 2000; and Bernard and Bradford, 2004). Importing firms 
may receive technological as well as better inputs, which can potentially help firms to enhance their productivity 
performance. Size of firms is accommodated in the model by using logged value of sales of firms. Theoretically, 
because of economies of scale, a larger size and increasing output should have a positive influence on the 
productivity of firms. Therefore, we expect positive sign of this variable as well.  
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Mairesse, 1995) and for Taiwan (Wang and Tsai, 2003). However, it is larger than that of US 
(Mairesse and Hall, 1996), UK (Kafouros, 2005) and Japan (Sassenou, 1988). The impact of 
foreign firm dummy is also found to be significant and positive on TFP (see column 3), which 
suggests that foreign firms are more productive than the local firms in the industry. Surprisingly, 
the estimated coefficient of the interaction variable of R&D to foreign firm dummy is found to 
be sizably large (0.36) (see column 3 of Table 5). This can be interpreted as 1% increase in R&D 
intensity of foreign firms’ leads to 0.36% increase in their TFP, which is one of the largest 
findings in a comparison with that of related literature. Further, the results regarding the trade 
variables i.e. export and import intensities are not found to have any significant effect on the 
productivity. However, size of firm (which measures economies of scale) seems to be crucial as 
coefficient of this variable found to be sizable, positive and statistically significant on the 
productivity.   
Table 5: Effects of R&D on TFP, 1994-2006 
 1 2 3 4 
Ln(R&Dint)  0.1925* 
(1.943) 
0.1516* 
(1.983) 
0.1542* 
(1.994) 
 
Ln(Export)  -0.0093 
(-0.999) 
-0.3742 
(-0.374) 
-0.0034 
(-0.384) 
Ln(Import)  -0.0070 
(-0.483) 
-0.004 
(-0.291) 
-0.0096 
(-0.673) 
Ln(size)  0.1289* 
(13.391) 
0.0096* 
(13.324) 
0.1292* 
(13.401) 
Foreign Firm 
Dummy (FD) 
  0.0157* 
(3.347) 
 
TFP(-1)  -0.1857* 
(-9.719) 
0.0196* 
(-10.228) 
-0.1814* 
(-9.691) 
Ln(R&Dint) * 
FD 
   0.3632* 
(1.955) 
Constant 0.3512 
(41.33) 
0.0601* 
(9.1159) 
0.0617* 
(9.329) 
0.0592* 
(9.018) 
R2 0.1630 0.34932 0.35838 0.3489 
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Notes:  
1. t-values in parentheses.  
2. * indicates statistical significance at 5% level. 
3. Estimation technique is Random GLS.  
 
5.2. Effects of R&D on Output 
 
Next we shift our attention to estimate the impact of R&D capital on output of our sample firms. 
In so doing, a production function approach is utilized, a la Griliches (1980), Schankerman 
(1981) Bartelsman et al., (1996) and Branstetter and Chen (2006). Here our base-line 
specification is: 
ititititit DcapRLnNLnKLnYLn εαααα ++++= )&()()()( 3210      ……………..3 
 where Y, N, K and R&Dcap represent value added, labor, physical capital and R&D capital, 
respectively. R&D capital is a measurement of the stock of knowledge possessed by a firm at a 
given point of time.7Ln, i and t denote logarithms of the variables, firm and year, respectively. 1α
, 2α and 3α are parameters to be estimated. We are especially interest in 3α , because this is the 
measure of output elasticity to R&D capital.  
We estimate equation 3, by three estimators: fixed effect, random effect and system GMM. 
Estimating the model using Ordinary Least Squares (OLS) with fixed or random effect usually 
provides estimates that are generally consistent with a priori knowledge of factor shares and 
constant returns to scale (Griliches and Mairesse, 1995). However, the procedure may produce 
biased and inconsistent estimates in the presence of endogeneity (Griliches, 1979). Therefore, 
following O’Mahony and Vecchi (2009), we also apply system GMM. The technique 
significantly reduces the weak correlation problem, and has proved to give more reasonable and 
reliable results in the context of production function estimation (Blundell and Bond, 2000). 
The estimated result of equation 3 is presented in Table 6. The system GMM estimator 
significantly reduces the size of parameters of labor and capital in comparison with estimate of 
fixed and random. However, the coefficient of our prime interest, R&D capital is almost 
                                                 
7 It’s important to note that two measures of R&D are used in the analysis. We have tested the R&D impact on TFP 
by using R&D intensity (a ratio of R&D expenditure to sale). While R&D capital is used as an input in the function 
therefore we use deflated expenditure on R&D activities and it is called R&D capital.  
 
 
15
invariant to the use of the estimators. Results of the estimations suggest that the output elasticity 
to R&D capital varies from 10% to 13%, implies 1% increase in R&D capital leads to 0.10 to 
0.13% growth in firms’ output. This estimate is broadly in accordance with the estimates of 
Griliches (1979, 1984) for the U.S., larger however than that of Branstetter and Chen, (2006) for 
Taiwan, and O’Mahony and Vecchi, (2009) for three European countries.  Also, our estimated 
elasticity is substantially larger than that of Raut (1995) for India, who finds it significant, 
however, a lower of the magnitude (0.016%).  
Table 6: Effects of R&D on Output of Firms, 1994-2006 
Variables  (1)FE (2)RE (3)System GMM 
Ln(K) 0.243* 
(5.74) 
0.257* 
(7.71) 
0.147* 
(2.58) 
Ln(N) 0.489* 
 (11.75) 
0.553* 
(16.44) 
0.381* 
(8.14) 
Ln(R&DCap)   0.117* 
(5.34) 
  0.132* 
(6.57) 
0.101* 
(3.53) 
Sargan  
 
   0.171 
R2 0.9141 0.9147  
Notes:  
1. t-values in parentheses.  
2. * indicates statistical significance at 5% level. 
3. Sargan is the p-value from the Sargan (1958) test of over-identifying restrictions, which test 
the overall validity of instruments for the GMM estimators. 
4.  FE and RE denote fixed effect and random GLS estimator, respectively. 
 
6. Conclusion and Policy Suggestions  
Findings of this study suggest that in-house R&D activities of firms are crucial determinates of 
productivity and output of the Indian pharmaceutical firms. The evidence clearly that suggests 
R&D firms are more efficient than non- R&D firms at least in the recent years. Furthermore, 
results of the regression analysis suggest that R&D intensity has a strong, positive and significant 
effect (15%) on TFP growth. This estimate is slightly larger than the findings of the international 
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studies. The results also confirm that foreign firms operating in the industry are more sensitive 
towards R&D activates than the local firms, as interaction of their dummy with the R&D 
variable yield elasticity to 0.36, which is meant that 1% increase in R&D intensity of foreign 
firms leads to 0.36% growth in their TFP. Finally, we investigate the effects of R&D capital on 
firms’ output under the production function framework. The results indicate that the output 
elasticity to R&D capital varies from 0.10 to 0.13, implies 1% increase in R&D capital leads to 
0.10 to 0.13% growth in firms’ output. This finding is moderate in a comparison with the 
estimated elasticity for other countries.  The estimated size of the elasticity in the Indian 
pharmaceutical in this study is equivalent to that of Griliches (1979, 1984) for the U.S., 
substantially larger however than that of Branstetter and Chen, (2006) for Taiwan, and 
O’Mahony and Vecchi, (2009) for three European countries. Therefore, we support the argument 
that ‘manna from heaven’ impact is large and significant.  
Considering the findings of this study on the crucial role of R&D in stimulating output and 
productivity, it is a worrying factor that the Indian pharmaceutical is characterized by low R&D 
intensity.  Thus, the policy suggestion is straightforward that the government should encourage 
firms for R&D activities through different ways which may include fiscal incentives, training 
and institutional collaboration. Moreover, foreign firms are found to be proactive in R&D 
activities, which will perhaps have a positive spillover effect for the others firms in the long run 
therefore flows of foreign direct investment in industry should also be encouraged. Finally, 
considering the findings in this study regarding the important role of in-house innovation 
activities of firms, we propose for further research in this area especially in developing countries 
using micro-level data. 
Appendix 
Table 1A. Descriptive Statistics on the Sample Firms, 1994-2006 
 
Variable  Mean 
Standard 
Deviation. 
Minimum Maximum 
LY 0.946 0.844 -1.824 2.902 
LK 1.1135 0.770 -1.076 2.986 
LN 2.788 0.853 0.229 4.648 
TFP 0.359 0.099 0.051 0.834 
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LExport   0.166 0.217 0 1 
LImport 0.114 0.142 0 0.988 
LR&DIntensity 0.014 0.032 0 0.588 
LR&DCap   -.050 0.948 -2.117 2.554 
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